Theraclion SA (TCLIF)
| Previous close | 0.5900 |
| Open | 0.5900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.5900 - 0.5900 |
| 52-week range | 0.5900 - 2.2800 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 26.083M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Theraclion Announces 2023 Financial Results and Continues Its Roadmap
MALAKOFF, France, March 27, 2024--Regulatory News: THERACLION (ISIN : FR0010120402 ; Mnemo : ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, presents its 2023 financial results and reviews the execution of its strategy.
- Business Wire
Theraclion Pursues Its Strategy and Announces Its 2023 Revenue
MALAKOFF, France, January 29, 2024--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE) (Paris:ALTHE), an innovative company developing a scalable robotic platform for non-invasive focused ultrasound therapy (HIFU), announces today the continued execution of its value creation strategy and its turnover for 2023. One of its mainstays, sale of consumables for varicose veins, is up by a substantial 61%.
- Business Wire
Theraclion Delivers Its 2023 Strategic Objectives
MALAKOFF, France, December 14, 2023--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for non-invasive ultrasound therapy, is now taking stock of its achievements over 2023.
